undamentalytics Newsletter
Sign in

Pyxis Oncology, Inc. income statement

In fiscal 2025, Pyxis Oncology, Inc. reported revenue of $13.9m, down 14.2% on the year before, operating income of −$84.4m (a -609.2% margin) and net income of −$79.6m, or −$1.28 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2024Dec 20242025Dec 2025
Revenue1614
Cost of revenue02
Gross profit1611
Research and development5974
General and administrative2522
Operating income−89−84
Income before tax−79−78
Income tax−21
Net income−77−80
Diluted EPS−$1.32−$1.28
Diluted shares (average)58m62m
EBITDA−86−80

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: KROS vs PYXSPRQR vs PYXSCTMX vs PYXS

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Pyxis Oncology, Inc.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Pyxis Oncology, Inc.